Eli Lilly (LLY) is set to report fourth-quarter earnings before the bell Thursday, with analysts expecting rising sales and profit in the first full quarter since the company's weight-loss drugs were declared no longer in shortage.

Analysts are bullish on the maker of weight-loss drugs Zepbound and Mounjaro, with 10 of the 11 analysts who follow the company and are tracked by Visible Alpha rating Eli Lilly stock as a "buy," along with one 澳洲幸运5官方开奖结果体彩网:"hold" rating. The lone hold rating is also the only analyst with a price ta🦩rget 🌺below the stock's current level, with the average price target at almost $986—a premium of about 19% above Tuesday's closing price.

Eli Lilly is expected to report $13.56 billion in revenue, up 45% year-over-year as the weight-loss drugs have boosted Eli Lilly's revenue over the last several quarters. 澳洲幸运5官方开奖结果体彩网:Net income is projected to more than double from the same time last year to $4.52 billion, or $4.99 per share, according to estimates compiled by Visible Alpha.

Earnings Follow Lowered Sales Forecast

Eli Lilly's earnings comes after the drugmaker again lowered expectations for its 澳洲幸运5官方开奖结果体彩网:fourth-quarter sales last month and its 澳洲幸运5官方开奖结果体彩网:third-quarter results disappointed in October.

The company said in January that sales of Mounjaro and Zepbound had grown slower than expected in the latest quarter, with fourth-quarter and full-year revenue expected to come in around $13.5 billion and $45 billion, respectively. CEO David Ricks also said in January that the company expects production of "salable doses" of its weight-loss drugs to be 60% higher in the first half of this year compared with that period in 2024.

Eli Lilly and weight-loss drugmaker rival Novo Nordisk (NVO), which makes Ozempic and Wegovy, have watched demand continuously 澳洲幸运5官方开奖结果体彩网:outpace their supply of the weight-loss drugs. Lilly's drugs 澳洲幸运5官方开奖结果体彩网:were removed from the Food and Drug Administration's shortage list 澳洲幸运5官方开奖结果体彩网:late last year, and the companies have each 澳洲幸运5官方开奖结果体彩网:spent billions on increasing their production capacity.

Eli Lilly shares have gained about 17% over the last 12 months, at $826.07 as of Tuesday's close.

UPDATE—Feb. 4, 2025: This article has been updated to reflect more recent analyst estimates and share price values.